Log in to save to my catalogue

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic ste...

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic ste...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d920693ad8d842c78b29bd1b15141947

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

About this item

Full title

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Publisher

London: Nature Publishing Group UK

Journal title

Communications biology, 2021-05, Vol.4 (1), p.569-569, Article 569

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilization in vivo. Here we show that while AMD11070 acts...

Alternative Titles

Full title

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d920693ad8d842c78b29bd1b15141947

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d920693ad8d842c78b29bd1b15141947

Other Identifiers

ISSN

2399-3642

E-ISSN

2399-3642

DOI

10.1038/s42003-021-02070-9

How to access this item